BACKGROUND: The study analyzes changes in lung function, pulmonary pressure and diffusing capacity of the lung in patients with mitral valve regurgitation (MR) treated by MitraClip implantation. METHODS: A total of 43 patients (19 women and 24 men with an average age of 78.0 ± 6.6 years) who were able to perform pulmonary function testing including diffusing capacity of the lung for carbon monoxide (DLCO), vital capacity (VC), total lung capacity (TLC), residual volume (RV) and forced expiratory volume in 1 s (FEV1) before and 6 weeks after MitraClip implantation participated in this study. Furthermore, clinical and echocardiographic parameters including systolic pulmonary artery pressure (sPAP), left ventricular ejection fraction (LVEF) and left atrial diameter (LAD) measurements were recorded in all patients. RESULTS: The procedure was performed successfully in all 43 patients leading to a reduction of MR in 97.7% of cases. One patient died on day 4 after the intervention most likely due to pulmonary artery embolism. Six weeks after the implantation 79.1% of patients showed a MR of at most mild to moderate. Furthermore, we could demonstrate a significant reduction of systolic pulmonary artery pressure during follow-up (from 48.8 ± 11.4 mmHg to 42.9 ± 9.0 mmHg (t(41) = - 2.6, p = 0.01). However, no changes in LVEF were detected. Comparing pre and post implant lung function tests, no significant alterations were seen for VC, TLC, DLCO and FEV1. Though, in a subgroup of patients with moderate to severe preexisting deterioration of DLCO at the baseline (max. 50%) the MitraClip procedure resulted in a significant improvement in DLCO (37.8% ± 9.0 to 41.6% ± 10.0, p < 0.001). CONCLUSIONS: Treatment of MR with the MitraClip system successfully reduces MR severity in the vast majority of patients. Consecutively, a reduction in pulmonary pressure could be observed, however no changes in LVEF were obvious. Lung function tests remained unaltered during follow-up. However, in a subgroup of patients with severe preexisting deterioration of DLCO the MitraClip procedure resulted in a significant improvement in DLCO. TRIAL REGISTRATION: Name of the registry: Die Auswirkung der interventionellen Mitralklappenreparatur mit MitraClip-System auf die Ergebnisse der Lungenfunktionsmessung. TRIAL REGISTRATION NUMBER: DRKS00022435; Date of registration: 09/07/2020 'Retrospectively registered'; URL of trial registry record: https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00022435 .

Clinical Study Center Berlin Institute of Health at Charité Universitätsmedizin Berlin Charitéplatz 1 10117 Berlin Germany

Department of Cybernetics Faculty of Electrical Engineering Czech Technical University Prague Prague Czech Republic

Department of Internal Medicine and Cardiology Pirna Hospital Pirna Germany

See more in PubMed

Asgar AW, Mack MJ, Stone GW. Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations. J Am Coll Cardiol. 2015;65(12):1231–1248. doi: 10.1016/j.jacc.2015.02.009. PubMed DOI

Baumgartner H. The 2017 ESC/EACTS guidelines on the management of valvular heart disease : What is new and what has changed compared to the 2012 guidelines? Wien Klin Wochenschr. 2018;130(5–6):168–171. doi: 10.1007/s00508-017-1297-5. PubMed DOI

Harb SC, Griffin BP. Mitral valve disease: a comprehensive review. Curr Cardiol Rep. 2017;19(8):73. doi: 10.1007/s11886-017-0883-5. PubMed DOI

Dery JP, et al. Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTudy (COAPT) Am Heart J. 2016;181:26–34. doi: 10.1016/j.ahj.2016.07.014. PubMed DOI

Puls M, et al. One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry. Eur Heart J. 2016;37(8):703–712. doi: 10.1093/eurheartj/ehv627. PubMed DOI PMC

Kottenberg E, et al. The minimally invasive MitraClip procedure for mitral regurgitation under general anaesthesia: immediate effects on the pulmonary circulation and right ventricular function. Anaesthesia. 2014;69(8):860–867. doi: 10.1111/anae.12712. PubMed DOI

Stadler S, Mergenthaler N, Lange TJ. The prognostic value of DLCO and pulmonary blood flow in patients with pulmonary hypertension. Pulm Circ. 2019;9(4):2045894019894531. doi: 10.1177/2045894019894531. PubMed DOI PMC

Todd N, Lai YC. Current understanding of circulating biomarkers in pulmonary hypertension due to left heart disease. Front Med (Lausanne) 2020;7:570016. doi: 10.3389/fmed.2020.570016. PubMed DOI PMC

Yuba K. A study on the pulmonary functions and the pulmonary circulation in cardio-pulmonary diseases. I. Pulmonary diffusing capacity in cardio-pulmonary diseases. Jpn Circ J. 1971;35(11):1391–1397. doi: 10.1253/jcj.35.11_1391. PubMed DOI

Stanescu D, Veriter C. A normal FEV1/VC ratio does not exclude airway obstruction. Respiration. 2004;71(4):348–352. doi: 10.1159/000079638. PubMed DOI

Mustafa KY, et al. Pulmonary function before and sequentially after valve replacement surgery with correlation to preoperative hemodynamic data. Am Rev Respir Dis. 1984;130(3):400–406. PubMed

Zou RH, Wallace WD, Nouraie SM, Chan SY, Risbano MG. Lower DLco% identifies exercise pulmonary hypertension in patients with parenchymal lung disease referred for dyspnea. Pulm Circ. 2020;10(1):2045894019891912. doi: 10.1177/2045894019891912. PubMed DOI PMC

Maor E, Raphael CE, Panaich SS, Reeder GS, Nishimura RA, Nkomo VT, Rihal CS, Eleid MF. Acute changes in left atrial pressure after mitraclip are associated with improvement in 6-minute walk distance. Circ Cardiovasc Interv. 2017;10(4):e004856. doi: 10.1161/CIRCINTERVENTIONS.116.004856. PubMed DOI